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Objectives: To identify factors associated with failure of telaprevir- and boceprevir-
based HCV triple therapy at a tertiary referral center in New York. MethOds: 
Records of 223 patients with genotype 1 HCV mono-infection who initiated triple 
therapy with peg-IFN/RBV plus telaprevir or boceprevir between 5/2011 and 3/2012 
were reviewed. Data were analyzed on an intention-to-treat basis by multivari-
able logistic regression and classification and regression tree models. Results: 
Overall, 172 patients were on telaprevir and 51 were on boceprevir. Median age 
was 57 years, 35% were female, 18% were black, 44% had F3-F4 fibrosis (Fib-4 ≥ 
3.25), 31% were naïve to treatment, 53% had genotype 1a, and 9% of those tested 
had IL28B CC genotype. Overall, 48% completed the expected course of therapy. 
Treatment failure (58% of patients) was associated with insufficient viral suppres-
sion or breakthrough (30%), adverse events (14%), relapse (12%), and loss to follow 
up (2%). Black race increased the risk of failure (OR: 5.92; 95% CI: 2.34-14.96), whereas 
HCV genotype 1b (OR:0.36; 95% CI: 0.18-0.69), higher platelets (OR: 0.91 per 10x103/
µL; 95% CI: 0.86-0.96), and IL28B CC genotype (OR: 0.28; 95% CI: 0.10-0.84) decreased 
the risk. In a classification tree, platelets < 137 x 103/µL were the strongest predictor 
of non-SVR24. The absence of HCV RNA at week 4 (telaprevir) or week 8 (boceprevir) 
were the only on-treatment variables independently (and inversely) related to non-
SVR. cOnclusiOns: Low platelets were an important negative predictor, suggest-
ing that treatment may be more effective if initiated before the onset of advanced 
liver disease and thrombocytopenia.(NIDA031095,NIDDK090317,Janssen)
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Objectives: Three PCVs (7-, 10-, and 13-valent) have been launched in Taiwan; 
only PCV10 and PCV13 are available in the current market. The City immunization 
program (CIP) in New Taipei City (NTC) started offering one dose of PCV in 2007 for 
children aged 2-5. PCV7 was provided initially and switched to PCV13 in 2012. To 
date, there is no research on the effectiveness of PCVs in Taiwan. This study evalu-
ated the real-world impact of PCVs on invasive pneumococcal disease (IPD) in NTC, 
the largest population city in Taiwan. MethOds: Data were derived from National 
Immunization Information System and National IPD Reporting System. Descriptive 
analysis was applied to summarize the vaccination trend and characteristics of 
IPD cases. The risk of IPD from vaccine-covered serotypes with PCV was estimated 
using incidence rate ratio (IRR), and the vaccine effectiveness was calculated as 
1- IRR. Vaccinated was defined as children who had at least one dose of PCV. If 
multiple PCVs were used, children were assigned to the PCV with more covered 
serotypes. Results: Total of 321,631 children born in NTC between Jan 1st, 2004 
and June 30th, 2013 were included. There were 183,342 children (58%) vaccinated; 
among these 46.0%, 51.7%, and 1.4% with PCV7, PCV13, PCV10, respectively. PCV10 
was excluded for the risk analysis, due to low utilization. Among 152 identified 
IPD cases, 84 cases (55.3%) were caused by serotype 19A. Most events occurred in 
children 3 (21.7%) and 2 (21.1%) years of age. The adjusted IRR of IPD (PCV-7 covered 
serotypes) for PCV7 was 0.29 (p= 0.012); VE 71%. The adjusted IRR of IPD for PCV13 
(PCV-13 covered serotypes) was 0.2 (p= 0.001); VE 80%. cOnclusiOns: Due to the 
CIP, over half of children 5 years and younger received a PCV in NTC. PCV vaccination 
significantly reduced the risk of IPD.
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Objectives: Influenza burden might be reduced by replacing current trivalent 
influenza vaccines (TIV, containing one B lineage) with quadrivalent vaccines 
(QIV, containing both Yamagata and Victoria influenza B lineages). This study 
(ClinicalTrials.gov: NCT01599390) assessed the potential added benefit of QIV 
versus TIV use on the prevention of influenza-attributable hospitalizations and 
deaths in the United States during 12 influenza seasons (July 1997–April 2009) 
as a consequence of preventing influenza B lineage mismatch. MethOds: 
Hospitalization and mortality data from the Nationwide Inpatient Sample and 
National Vital Statistics System databases, respectively, were used to quantify the 
influenza-attributable burden through virus-guided regression models. Based on 
Reed’s probability model (Reed et al, Vaccine 2012;30:1993-8), a simple multiplier 
model was developed to estimate the “respiratory disease broadly defined” (RDBD) 
outcome rates had B lineage mismatch seasons been avoided. Hospitalizations 
with primary, and deaths with any mention of RDBD diagnostic codes (respiratory 
disease, cough, abnormalities of breathing, fever or viral infections not other-
wise specified) were considered influenza-attributable. The model used avail-
able vaccine coverage data (primary source: CDC Morbidity & Mortality Weekly 
Reports; secondary sources: National Health Interview Survey reports, National 
Immunization Survey, Behavioral Risk Factor Surveillance System) and vaccine 
effectiveness values from the literature. Results: The highest numbers of QIV-
preventable hospitalizations and deaths were attributed to ≥ 75-year-olds: 3,141 
and 461 on average per season, respectively. During the worst mismatched season 
(2007/2008), across all ages, 41% and 28% of influenza-attributable hospitalizations 
medication therapy for diabetes increased from 11.8 to 17.6 million, but the per-
centage of patients receiving prescription medication for diabetes dropped from 
90.5% to 87.5% (p< .001). The mean number of physician’s office visits for treating 
diabetes increased from 45.9 million in 2002 to 55.9 million in 2010, while the 
mean number of visits per treated patient declined from 4.7 to 3.9 during the 
same period. Among the patients used prescription medications, the proportion of 
those using both insulin and oral anti-diabetic medications increased from 14.9% 
in 2002 to 18.4% in 2010. For specific classes of oral anti-diabetic medications, the 
percentage using biguanides increased from 40.1% to 60.5%, in the contrast, use 
of sulfonylureas and thiazolidinediones dropped from 50.1% to 36.1% and 20.7% to 
12.8% respectively. The annual expenditures per user for medications for treating 
diabetes increased from $889 in 2002 to $1026 in 2010. Increasing use of newer 
insulin and thiazoliones was the main driver of recent increases in the medica-
tion expenditures ($10.5 billion in 2002 to $18.1 billion in 2007). cOnclusiOns: 
Increasing costly medication therapy for diabetes is being applied to an increasing 
population. However, the percentage of diabetes patients received medication 
treatment slightly dropped. This suggests that much more attention should be 
directed in reducing the gap between treatment need and use as well as evaluation 
of more costly medication therapy for diabetes.
INFectIoN – clinical outcomes studies
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aNaPhylaxIs adverse eveNts WIth 3rd geNeratIoN cePhalosPorINs: 
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admINIstratIoN adverse eveNt rePortINg system (Faers)
Pawar A.M., Caffrey A.R.
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Objectives: Anaphylaxis is a serious allergic reaction that has been reported as a 
rare adverse drug reaction (ADR) in cephalosporin antibiotics, predominantly cef-
triaxone, causing several deaths. We aimed to evaluate reports of anaphylaxis with 
3rd generation cephalosporins (ATC code= J01DD) using a disproportionality analysis 
of spontaneous adverse event reports. MethOds: Our case-control study identified 
anaphylaxis (cases) or other adverse events (controls) in FAERS from January 2004 to 
September 2012 for 3rd generation cephalosporin antibiotics. Reporting odds ratio 
(ROR) and proportional reporting ratio (PRR) were calculated to estimate risk for 
each 3rd generation cephalosporin. Only primary suspected drugs and initial status 
of reports were studied. Results: Of 9315 eligible ADR reports for 3rd generation 
cephalosporins, 278 (3%) anaphylaxis ADRs were reported, with 100 (36%) deaths, 
68 (25%) hospitalizations, and 52 (19%) life-threatening events. Ceftriaxone was the 
most commonly reported cephalosporin exposure among anaphylaxis cases (n= 189, 
67.9%). Of the anaphylaxis cases associated with ceftriaxone, death was reported in 
43%, hospitalization in 24%, and life-threatening events in 21% of cases. The odds 
of exposure was significantly higher with cefoperazone (ROR 3.88, 95% confidence 
interval [CI] 2.71-5.56) and ceftriaxone (ROR= 1.92, CI= 1.49-2.48) and significantly 
lower with cefdinir (ROR= 0.15, CI= 0.08-0.29) and cefotaxime (ROR= 0.31, CI= 0.12-
0.84) among cases compared to controls. Similarly, PRR indicated a significantly 
increased risk of anaphylaxis with cefoperazone (PRR= 3.60, CI= 2.60-5.00) and cef-
triaxone (PRR= 1.89, CI= 1.47-2.42) and a significantly decreased risk with cefdinir 
(PRR= 0.16, CI= 0.08-0.29) and cefotaxime (PRR= 0.32, CI= 0.12-0.85) as compared to 
controls experiencing non-anaphylaxis adverse events. Both ROR and PRR were non-
significant for cefditoren, cefpodoxime, ceftazidime and ceftibuten. cOnclusiOns: 
Among 3rd generation cephalosporins, which are commonly used to treat bacte-
rial infections, patients having anaphylaxis ADRs were found to have significantly 
higher odds of cefoperazone and ceftriaxone exposure, but significantly lower odds 
of cefdinir and cefotaxime exposure compared to patients having other ADRs.
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aNtIBIotIc treatmeNt PatterNs assocIated WIth PersoNs NeWly-
dIagNosed WIth lyme dIsease IN the uNIted states
Miller J.D., Bonafede M.M.
Truven Health Analytics, Cambridge, MA, USA
Objectives: The objective of this study was to describe the antibiotic treatment 
patterns among patients with newly-diagnosed Lyme disease (LD). Some published 
treatment guidelines specify short-course antibiotic treatment for early LD lasting 
10-28 days, but there are conflicting recommendations. Little is known about real-
world LD treatment patterns. MethOds: Patients newly diagnosed with LD (ICD-9: 
088.81) in 2010-2012 were identified in the Truven Health MarketScan® Commercial 
and Medicare Supplemental Databases. Continuous enrollment was required one 
year pre- and three months post-LD diagnosis. Patients were excluded if they used 
antibiotics in the prior 90 days or had another infection diagnosis in the week 
prior to or following the index LD diagnosis. Outcomes were the portion of patients 
receiving antibiotics within 14 days post-LD diagnosis, as well as duration and 
types of antibiotics received. Results: A total of 10,783 patients met the selec-
tion criteria (mean age 42.0 years [SD= 20.6]; 44% female). Of these patients, 64% 
initiated antibiotic therapy within 14 days of their index LD diagnosis. On average, 
patients used antibiotics for 28.3 (SD= 27.4, median= 21.0) days following a new LD 
diagnosis. The majority of patients (78.3%) were treated with antibiotics for 10-30 
days; relatively few patients (3%) were treated for less than 10 days. A substan-
tial portion (18.7%) were treated with antibiotics for more than one month, with 
some treated for more than two (5.3%) or three months (2.9%). Newly-diagnosed LD 
patients were treated primarily with types of antibiotics mentioned in published 
treatment guidelines (doxycycline [73%], amoxicillin [22%], cefuroxime [4%]), with 
very little use of antibiotics deviating from guidelines (e.g., azithromycin [3%] and 
ciprofloxacin [1%]). cOnclusiOns: Optimal treatment for newly-diagnosed LD 
remains undefined. Results of this study substantiate anecdotal evidence that a 
substantial portion of LD patients are being treated with antibiotics for longer than 
advocated in published guidelines or not at all.
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atric hospitalizations. Wilcoxon rank sum test was used to determine differences 
in hospital LOS. Results: Overall, these data represent over 4.6 million pediatric 
hospital discharges for SSTIs nationwide from 2001 to 2010. The rate of hospitaliza-
tion for SSTIs increased 60%, from 491/10,000 in 2001 to 784/10,000 in 2010. S. aureus 
SSTIs increased over the study period from 6/10,000 in 2001 and peaked at 37/10,000 
in 2008. This was mostly attributable to the dramatic increase in MRSA SSTIs, from 
1.3 cases per 10,000 in 2001 to 31.4 cases per 10,000 in 2010. Additionally, MSSA SSTIs 
nearly tripled throughout the study period (4 per 10,000 in 2001 to 12 per 10,000 in 
2010). The median (interquartile range) hospital LOS for S. aureus SSTIs significantly 
decreased from 3 (2-5) days in 2001 to 2 (1-3) days in 2010 (P< 0.001). cOnclusiOns: 
The incidence of MSSA and MRSA SSTI hospitalizations among U.S. children has 
dramatically increased from 2001 to 2010.
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Objectives: To characterize types of hospitals and patients contributing to the 
prevalence of ABSSSI hospital admissions and describe recent admission trends in 
the US. MethOds: We conducted a retrospective database analysis of adult (≥ 18 
years) hospital admissions with a principal ICD-9 diagnosis of ABSSSI: 681.XX, 682.
XX, 686.XX, 958.3, 998.5X, or 035 using the US Healthcare Cost and Utilization Project 
National Inpatient Sample (HCUP NIS), representing over 1,000 hospitals with > 8 
million hospital stays annually from 2005-2011. Descriptive and bivariate analysis 
was performed. HCUP specified weights were used for national estimates. Results: 
From 2005-2011, there were 4,891,187 adult ABSSSI hospital admissions (2% of all 
HCUP NIS admissions), with admissions increasing 17.3% across this timeframe 
(p< 0.0001). ABSSSI patients were primarily male (50.8%), white (60.3%), mean age 
55.7 years (±18.6 yrs), Medicare (40.7%), and discharged to home (53.8%). Patients 
were of moderate severity of illness (43.5% APR-DRG II) with minor risk of mortality 
(60.4% APR-DRG I). Comorbidities included diabetes without complications (25.2%), 
COPD (17.2%), and CHF (10.3%) and increased over time (p≤ 0.0001). Hospitals were 
in urban areas (85.4%), in the South (39.0%), of large bed size (> 325 beds by region, 
59.1%), private (71.0%), and with non-teaching status (55.3%). Majority of admissions 
were other cellulitis and abscess (682.XX, 73.5%) and post-operative wound infection 
(998.5X, 21.5%). Post-traumatic (958.3, n= 13,952) and post-operative wound (998.5X, 
n= 1,048,916) infection incurred the greatest mean length of stay (7.2 vs 6.7 days, 
respectively vs 4.7 days average across ABSSSI codes). Mortality was 0.5% overall and 
was highest among post-operative wound infection patients (1.1%). cOnclusiOns: 
More ABSSSI patients enter the US hospital system each year with a greater propor-
tion having comorbidities. As the population continues to age, alternative settings 
for treating ABSSSI patients may lessen the burden on the hospital system and 
reduce potential risks associated with a hospital stay.
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the uNIted states
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Objectives: Infants are at greatest risk for severe pertussis (~50% of infant cases 
require hospitalization). Recent surveillance indicates a resurgence of overall per-
tussis incidence in the US, but limited data exist on whether severe infantile cases 
are also resurging and the extent to which severe pertussis incidence in infants var-
ies by sex and race. We therefore assessed recent US trends in overall and sex- and 
race-stratified incidence of infant pertussis-related hospitalizations. MethOds: 
Data on pertussis-related hospitalizations (ICD-9-CM discharge codes 033.0, 033.8, 
033.9, 484.3) from the 2000-2011 Nationwide Inpatient Sample (NIS) were retrospec-
tively analyzed. Annual pertussis-related hospitalizations per 10,000 infants aged 
< 12 months was estimated using NIS sampling weights and year-specific population 
denominators from US census data. Results: Incidence of pertussis-related hos-
pitalization was ~6/10,000 infants between 2000 and 2003 before increasing sharply 
in 2004 (9.0/10,000) and 2005 (13.8/10,000). Thereafter, incidence fell substantially 
(6.2, 4.1, and 4.2/10,000 in 2006, 2007, and 2008, respectively) before increasing again 
in 2009 and 2010 (5.9 and 7.8/10,000, respectively). Incidence declined again in 2011 
(3.2/10,000). Incidence was similar between males and females, but substantial dif-
ferences were observed by race. Incidence was highest in Hispanic infants, starting 
at 8.6/10,000 in 2000, peaking at 24.9/10,000 in 2005, and then falling to 4.3/10,000 
in 2008 before another sharp increase to 14.7/10,000 in 2010. Incidence was lowest 
for white and Asian infants, reaching a 2005 peak of only 5.4 and 5.3/10,000, respec-
tively. cOnclusiOns: Infant pertussis hospitalizations peaked in 2005 before a 
sharp decline thereafter, possibly due to increased herd immunity conferred by 
the 2006 launch of universal adolescent Tdap vaccination. Incidence resurged again 
through 2010 before another decline in 2011, demonstrating for severe cases the 
documented cyclic pattern of peaks and nadirs for overall pertussis incidence. This 
analysis also highlights the need for increased focus on minorities in pertussis 
vaccination programs.
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Objectives: To examine the geographic, age, gender and racial variations in 
the prevalent population of Lyme disease using U.S Medicaid data. MethOds: 
Patients with Lyme disease were identified using International Classification of 
and deaths, respectively, may have been QIV-preventable. cOnclusiOns: The 
seasonal variability of influenza B lineage circulation and the level of vaccine 
match determine the extent of the benefit of QIV use. However, on average, under 
reasonable assumptions of vaccine effectiveness, a substantial number of hospi-
talizations and deaths could have been prevented by using QIV during the study 
period in the United States. Funding: GlaxoSmithKline Biologicals SA
PIN6
assocIatIoN BetWeeN INterFeroN use aNd reduced metaBolIc aNd 
vascular comPlIcatIoNs amoNg PatIeNts WIth hePatItIs c
Chirikov V.V.1, Shaya F.T.1, Howell C.D.2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School 
of Medicine, Baltimore, MD, USA
Objectives: We determined the association between interferon treatment for 
chronic hepatitis C (HCV) and the presence and severity of metabolic and vas-
cular complications over time in a high-risk Medicaid population. MethOds: 
This was a historical prospective cohort study using administrative claims data 
of Maryland Medicaid recipients (2006-2009) infected with hepatitis C. We used 
the validated Diabetes Complications Severity Index (DCSI) as proxy for the pres-
ence and severity of metabolic and vascular complications. The endpoint of the 
study was the change in DCSI score during three years of follow-up. At baseline, 
interferon-treated patients were matched 1:10 to non-treated patients for DCSI 
count, cirrhosis, end stage liver disease, race, and anti-diabetic therapy. We modelled 
the association between interferon use and the risk of the presence and increased 
severity of vascular and metabolic complications using a zero-inflated Poisson mul-
tivariate regression, stratified by White and Black race and adjusted for baseline 
covariates. Results: White persons treated with interferon for 24-48 weeks and 
longer than 48 weeks had a significantly smaller increase in DCSI score ranging 
from 53%-75% and 54%-69% over the study follow-up, respectively, compared to 
untreated persons. There was no significant difference in the change in DSCI scores 
in Blacks treated for either 24-48 weeks or longer than 48 weeks, though paradoxi-
cally Blacks treated for > 48 weeks had a borderline significant 45% higher DSCI 
score at 30 months of follow-up. In patients with a DSCI count of zero at baseline, 
both White (OR= 0.22, P= 0.01) and Black (OR= 0.38, P= 0.09) patients treated with 
interferon exhibited a lower risk of developing vascular/metabolic disease at 30 
and 36 months of follow-up, respectively. cOnclusiOns: The results suggest that 
interferon treatment for chronic HCV might decrease metabolic and vascular com-
plications related to diabetes.
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Objectives: Hepatitis C decreases health related quality of life (HRQL) which 
is further diminished by dual antiviral therapy. HRQL improves after successful 
treatment. This trial explores the course of and factors associated with HRQL in 
patients given individualized or standard treatment based on early treatment 
response. To study the relationship betweenv HRQL and mode of acquisition, treat-
ment discontinuations and treatment outcome in patients with chronic hepatitis 
C. MethOds: The Short Form SF-36 Health Survey was administered for evaluation 
health-related quality of life. Consecutive unselected Kazakh patients with chronic 
hepatitis C completed the SF-36 questionnaire before, during and after treatment 
with pegylated interferon and ribavirin before, during and after combination ther-
apy. Results: At baseline, HRQL was reduced in all SF-36 subscales in our patients 
as compared with the general Kazakh population by age, participating center, sever-
ity of liver disease and income. Exploring the course of HRQL (scores at follow up 
minus baseline), only the dimension general health increased. In this dimension 
patients with a relapse or sustained response differed from non-responders. Men 
and women differed in the dimension bodily pain. Treatment schedule did not influ-
ence the course of HRQL. cOnclusiOns: Kazakh patients with chronic hepatitis 
C have a marked reduction in their HRQL as compared to the general population. 
Main determinants of HRQL were severity of liver disease, age, gender, participating 
center and response to treatment. Our results do not exclude a more profound nega-
tive impact of individualized treatment compared to standard, possibly caused by 
higher doses and extended treatment duration in the individualized group. Antiviral 
therapy might have a more intense and more prolonged negative impact on females. 
Early dropouts from therapy have significantly lower HRQL scores at baseline than 
adherent patients, and sustained viral responders improve their HRQL significantly 
more than non-responders.
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Objectives: Estimating the burden of Staphylococcus aureus infections among U.S. 
children is important for planning appropriate prevention and treatment strategies. 
The objectives of this study were to characterize national estimates of S. aureus 
SSTIs in pediatric patients from 2001 to 2010 and assess trends in hospital length 
of stay (LOS). MethOds: This was a retrospective analysis of the U.S. National 
Hospital Discharge Surveys from 2001 to 2010. Eligible cases included children < 
18 years of age hospitalized with a principle ICD-9-CM diagnosis code for SSTI. 
S. aureus, methicillin-susceptible S. aureus (MSSA), and methicillin-resistant S. 
aureus(MRSA) were defined by ICD-9 CM diagnosis codes. Data weights were used 
to derive national estimates. Annual incidence rates were reported per 10,000 pedi-
